---
category: news
title: "Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc."
excerpt: "Based on data found in the circulating proteome and genome, Biodesix designs tests that support treatment decisions including patient selection for immunotherapies, novel therapy combinations ... combines Biodesixâ€™s strengths in test discovery and development, artificial intelligence, and their applications to immunotherapy, with the ..."
publishedDateTime: 2020-02-11T12:22:00Z
webUrl: "https://www.businesswire.com/news/home/20200211005158/en/Biodesix-Announces-Initiation-Clinical-Phase-Biomarker-Development"
type: article
quality: 0
heat: 0
published: false

provider:
  name: Business Wire
  domain: businesswire.com

topics:
  - AI
  - AI in Healthcare

images:
  - url: "https://mms.businesswire.com/media/20200211005158/en/772467/23/Biodesix_r_rgb.jpg"
    width: 1200
    height: 627
    title: "Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany and Pfizer Inc."

secured: "oiz42A4OVpWJQmnADhHzfYVw4oLo0bUKsDV9G0rmsLm3V2JF6nbf+X9b9AGsgeieHQdfPbkD16xwOBuAKzazx+yMzA38+7SEQKGgJQJMG/2ndvwHpKjQ5eLhNY4ASACKZhpAC/AD2bBedDT8C07ZlnKjiPqKEYPM6gNE0k+yY6LRBK999cimzxGzKd6rx7x30NfOPZ5GNlN9FAI/coBMfWmducQk6/kWrueRyj4UHc6jIKDJIURkFQzNY1XXpTSjgqPsSY02P0u9RoiRn0GlpBJahky7eICy2imFrEJ47iIwIAK9b//B1n6xapZCXVnI7YXIdXvI+rdn6keB+LdMViw4eoGM6jsba+90vS/si2dp67+LeG5Bj0YBhvk1ALXT1JJltPQ2mVUEFAkceLr183I9SNC9o+fnOTiLZ7ce5FPtFUK4nZpn0xnmtoreNND4JTO6/9iP9ppDWeS2r0MwRO09Rw+dwW6dNWhKiss2ALA=;EoE2fWdRtA3IxL0wDTDzuQ=="
---

